Three Vanderbilt University scientists on the forefront of research in cellular dynamics and cancer treatment will discuss their cutting-edge investigations during the next Flexner Discovery Lecture on Thursday, Sept. 21.

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science.

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

When former Nashvillian Carol O’Hare speaks about a specific group of physicians at Vanderbilt-Ingram Cancer Center (VICC), her voice softens, and she refers to them affectionately as “my fellows.”